{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:36:01Z","timestamp":1789763761153,"version":"4.0.1"},"reference-count":117,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>The expanding clinical utilization of immune checkpoint inhibitors (ICIs) in oncology has brought increasing attention to thyroid dysfunction as a prominent immune-related adverse event (irAE). Elucidating the pathophysiological mechanisms underlying ICI-induced thyroiditis represents a critical step toward developing evidence-based diagnostic protocols and targeted therapeutic interventions for cancer patients undergoing immunotherapy. This comprehensive review systematically examines current advances in understanding the etiopathogenesis of ICI-induced thyroiditis. First, we described pharmacological characterization of ICIs, then discussed multifactorial analysis of cellular and molecular contributors to thyroid autoimmunity following ICI administration and finally analyzed critical evaluation of emerging hypotheses regarding primary pathogenic drivers. Through this review, we aim to establish mechanistic connections between ICI pharmacodynamics and thyroid tissue immunopathology.<\/jats:p>","DOI":"10.3389\/fendo.2025.1584675","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:15:00Z","timestamp":1748996100000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Immune checkpoint inhibitor-induced thyroiditis and its potential mechanisms"],"prefix":"10.3389","volume":"16","author":[{"given":"Xueqian","family":"Mao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoming","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiameng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufei","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2022.101660","article-title":"Immune checkpoint inhibitor-related thyroid dysfunction","volume":"36","author":"Iwama","year":"2022","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1177\/1758835918764628","article-title":"Clinical assessment of immune-related adverse events","volume":"10","author":"Sosa","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11912-020-0897-9","article-title":"Immune-related adverse events (irAEs): diagnosis, management, and clinical pearls","volume":"22","author":"Darnell","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e008591","DOI":"10.1136\/jitc-2023-008591","article-title":"Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update","volume":"12","author":"Fletcher","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.649863","article-title":"Immune checkpoint inhibitors-related thyroid dysfunction: epidemiology, clinical presentation, possible pathogenesis, and management","volume":"12","author":"Zhan","year":"2021","journal-title":"Front Endocrinol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\u2606","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.3390\/ijms18122642","article-title":"Newly emerging immune checkpoints: Promises for future cancer therapy","volume":"18","author":"Torphy","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02306","article-title":"Immune checkpoints as therapeutic targets in autoimmunity","volume":"9","author":"Paluch","year":"2018","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"crossref","DOI":"10.1007\/978-981-15-3266-5_9","article-title":"Functions of immune checkpoint molecules beyond immune evasion","volume-title":"Regulation of Cancer Immune Checkpoints: Molecular and Cellular Mechanisms and Therapy","author":"Zhang","year":"2020"},{"key":"B12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1158\/0008-5472.CAN-14-2538","article-title":"Cancer immunotherapy and breaking immune tolerance: New approaches to an old challenge","volume":"75","author":"Makkouk","year":"2015","journal-title":"Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-021-02495-7","article-title":"Role of the PD-1\/PD-L1 signaling in multiple sclerosis and experimental autoimmune encephalomyelitis: recent insights and future directions","volume":"58","author":"Mi","year":"2021","journal-title":"Mol Neurobiol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1172\/JCI80011","article-title":"Anti\u2013PD-1\/PD-L1 therapy of human cancer: past, present, and future","volume":"125","author":"Chen","year":"2015","journal-title":"J Clin Invest"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216726","article-title":"PD-1 regulation in immune homeostasis and immunotherapy","volume":"588","author":"Gao","year":"2024","journal-title":"Cancer Lett"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.964442","article-title":"The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers","volume":"13","author":"Tang","year":"2022","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1198365","article-title":"Current understanding of CTLA-4: from mechanism to autoimmune diseases","volume":"14","author":"Hossen","year":"2023","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1172\/JCI145186","article-title":"Immune checkpoint inhibitor\u2013associated myocarditis: manifestations and mechanisms","volume":"131","author":"Moslehi","year":"2021","journal-title":"J Clin Invest"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination","volume":"13","author":"Boutros","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: A systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1210\/er.2013-1055","article-title":"Breaking tolerance to thyroid antigens: Changing concepts in thyroid autoimmunity","volume":"35","author":"McLachlan","year":"2014","journal-title":"Endocr Rev"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2023.04.002","article-title":"Immune mechanisms of toxicity from checkpoint inhibitors","volume":"9","author":"Wang","year":"2023","journal-title":"Trends Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1172\/JCI28993","article-title":"Interaction of mature CD3+CD4+ T cells with dendritic cells triggers the development of tertiary lymphoid structures in the thyroid","volume":"116","author":"Marinkovic","year":"2006","journal-title":"J Clin Invest"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-024-01947-5","article-title":"Tertiary lymphoid structures in diseases: immune mechanisms and therapeutic advances","volume":"9","author":"Zhao","year":"2024","journal-title":"Sig Transduct Target Ther"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2014.09.006","article-title":"Tertiary lymphoid structures in cancer and beyond","volume":"35","author":"Dieu-Nosjean","year":"2014","journal-title":"Trends Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-023-00706-z","article-title":"The roles of tertiary lymphoid structures in chronic diseases","volume":"19","author":"Sato","year":"2023","journal-title":"Nat Rev Nephrol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s12943-024-02126-4","article-title":"Deciphering the role of LGALS2: insights into tertiary lymphoid structure-associated dendritic cell activation and immunotherapeutic potential in breast cancer patients","volume":"23","author":"Li","year":"2024","journal-title":"Mol Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s40425-019-0736-4","article-title":"Tertiary lymphoid organs in the inflammatory myopathy associated with PD-1 inhibitors","volume":"7","author":"Matsubara","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf9419","article-title":"Tertiary lymphoid structures in cancer","volume":"375","author":"Schumacher","year":"2022","journal-title":"Science"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/bs.vh.2017.07.001","article-title":"Thyroid autoimmunity: An interplay of factors","volume":"106","author":"Merrill","year":"2018","journal-title":"Vitam Horm"},{"key":"B35","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jtbi.2014.12.015","article-title":"Thyroid autoimmunity as a window to autoimmunity: An explanation for sex differences in the prevalence of thyroid autoimmunity","volume":"375","author":"Merrill","year":"2015","journal-title":"J Theor Biol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2023.103072","article-title":"Single cell transcriptomic analysis of Graves\u2019 disease thyroid glands reveals the broad immunoregulatory potential of thyroid follicular and stromal cells and implies a major re-interpretation of the role of aberrant HLA class II expression in autoimmunity","volume":"139","author":"\u00c1lvarez-Sierra","year":"2023","journal-title":"J Autoimmun"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-1568","article-title":"Innate immune activation and thyroid autoimmunity","volume":"96","author":"Kawashima","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2009.00782.x","article-title":"Molecular mechanism and function of CD40\/CD40L engagement in the immune system","volume":"229","author":"Elgueta","year":"2009","journal-title":"Immunological Rev"},{"key":"B39","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.semcancer.2019.06.012","article-title":"Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review","volume":"64","author":"Khan","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2017.11.002","article-title":"Unique cytologic features of thyroiditis caused by immune checkpoint inhibitor therapy for Malignant melanoma","volume":"5","author":"Angell","year":"2018","journal-title":"Genes Dis"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002642","article-title":"Evaluating T-cell cross-reactivity between tumors and immune-related adverse events with TCR sequencing: pitfalls in interpretations of functional relevance","volume":"9","author":"Cottrell","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00841-0","article-title":"Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases","volume":"18","author":"Tison","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s00395-024-01068-8","article-title":"Molecular fingerprints of cardiovascular toxicities of immune checkpoint inhibitors","volume":"120","author":"Gergely","year":"2024","journal-title":"Basic Res Cardiol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0402","article-title":"Association of checkpoint inhibitor\u2013induced toxic effects with shared cancer and tissue antigens in non\u2013small cell lung cancer","volume":"5","author":"Berner","year":"2019","journal-title":"JAMA Oncol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s40425-019-0533-0","article-title":"Exceptional response and multisystem autoimmune-like toxicities associated with the same T cell clone in a patient with uveal melanoma treated with immune checkpoint inhibitors","volume":"7","author":"Rapisuwon","year":"2019","journal-title":"J immunotherapy Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1386362","article-title":"The T cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitors","volume":"7","author":"L\u00e4ubli","year":"2017","journal-title":"Oncoimmunology"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2019.04.102","article-title":"Correlation between thyroid transcription factor-1 expression, immune-related thyroid dysfunction, and efficacy of anti-programmed cell death protein-1 treatment in non-small cell lung cancer","volume":"11","author":"Koyama","year":"2019","journal-title":"J Thorac Dis"},{"key":"B48","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-3175","article-title":"Cancer neoantigens and applications for immunotherapy","volume":"22","author":"Desrichard","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B50","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.coi.2016.04.005","article-title":"Mass spectrometry-based antigen discovery for cancer immunotherapy","volume":"41","author":"Bassani-Sternberg","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2013.0170","article-title":"Autoimmune thyroid disease elicited by NY-ESO-1 vaccination","volume":"24","author":"Vita","year":"2014","journal-title":"Thyroid"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a007294","article-title":"Microbiota and autoimmunity","volume":"5","author":"Chervonsky","year":"2013","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2020.04.001","article-title":"The gut microbiota: emerging evidence in autoimmune diseases","volume":"26","author":"Zhang","year":"2020","journal-title":"Trends Mol Med"},{"key":"B54","doi-asserted-by":"publisher","first-page":"105427","DOI":"10.1016\/j.ebiom.2024.105427","article-title":"Gut microbiome metabolites, molecular mimicry, and species-level variation drive long-term efficacy and adverse event outcomes in lung cancer survivors","volume":"109","author":"Liu","year":"2024","journal-title":"eBioMedicine"},{"key":"B55","doi-asserted-by":"publisher","first-page":"111611","DOI":"10.1016\/j.celrep.2022.111611","article-title":"Cardiac myosin-specific autoimmune T cells contribute to immune-checkpoint-inhibitor-associated myocarditis","volume":"41","author":"Won","year":"2022","journal-title":"Cell Rep"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-016-9363-2","article-title":"Molecular mimicry and autoimmune thyroid disease","volume":"17","author":"Benvenga","year":"2016","journal-title":"Rev Endocr Metab Disord"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2019.05.008","article-title":"Microbiota and thyroid interaction in health and disease","volume":"30","author":"Fr\u00f6hlich","year":"2019","journal-title":"Trends Endocrinol Metab"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-024-01003-w","article-title":"The relationship between the gut microbiota and thyroid disorders","volume":"20","author":"Ludgate","year":"2024","journal-title":"Nat Rev Endocrinol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1817","article-title":"Mechanisms maintaining peripheral tolerance","volume":"11","author":"Mueller","year":"2010","journal-title":"Nat Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16071440","article-title":"Immune-related adverse events due to cancer immunotherapy: immune mechanisms and clinical manifestations","volume":"16","author":"Casagrande","year":"2024","journal-title":"Cancers"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.02.010","article-title":"Understanding subset diversity in T cell memory","volume":"48","author":"Jameson","year":"2018","journal-title":"Immunity"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-3296","article-title":"Tissue-resident T cells in clinical response and immune-related adverse events of immune checkpoint blockade","volume":"30","author":"Zhao","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01623-z","article-title":"T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma","volume":"28","author":"Lozano","year":"2022","journal-title":"Nat Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3001199","article-title":"PD-L1 signaling on human memory CD4+ T cells induces a regulatory phenotype","volume":"19","author":"Fanelli","year":"2021","journal-title":"PloS Biol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb7495","article-title":"CD4 + T cells are essential for the development of destructive thyroiditis induced by anti\u2013PD-1 antibody in thyroglobulin-immunized mice","volume":"13","author":"Yasuda","year":"2021","journal-title":"Sci Transl Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-023-01105-x","article-title":"CD8 T-cell subsets: heterogeneity, functions, and therapeutic potential","volume":"55","author":"Koh","year":"2023","journal-title":"Exp Mol Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adg0675","article-title":"Clonally expanded, thyrotoxic effector CD8+ T cells driven by IL-21 contribute to checkpoint inhibitor thyroiditis","volume":"15","author":"Lechner","year":"2023","journal-title":"Sci Trans Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110452","article-title":"Immunosensitivity mediated by downregulated AKT1-SKP2 induces anti-PD-1-associated thyroid immune injury","volume":"121","author":"Wu","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2023.101743","article-title":"Pathogenic role of Th17 cells in autoimmune thyroid disease and their underlying mechanisms","volume":"37","author":"Wang","year":"2023","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B70","doi-asserted-by":"publisher","first-page":"100868","DOI":"10.1016\/j.xcrm.2022.100868","article-title":"Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors","volume":"4","author":"Bukhari","year":"2023","journal-title":"CR Med"},{"key":"B71","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41590-022-01387-9","article-title":"TH17 cell heterogeneity and its role in tissue inflammation","volume":"24","author":"Schnell","year":"2023","journal-title":"Nat Immunol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"696","DOI":"10.4049\/jimmunol.2200244","article-title":"Inhibition of IL-17A Protects against Thyroid Immune-Related Adverse Events while Preserving Checkpoint Inhibitor Antitumor Efficacy","volume":"209","author":"Lechner","year":"2022","journal-title":"J Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-024-00810-4","article-title":"A targetable type III immune response with increase of IL-17A expressing CD4+ T cells is associated with immunotherapy-induced toxicity in melanoma","volume":"5","author":"Dimitriou","year":"2024","journal-title":"Nat Cancer"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.75","article-title":"The regulation of immune tolerance by FOXP3","volume":"17","author":"Lu","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"101580","DOI":"10.1016\/j.isci.2020.101580","article-title":"Uncoupling therapeutic efficacy from immune-related adverse events in immune checkpoint blockade","volume":"23","author":"Hu","year":"2020","journal-title":"iScience"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-20-0969","article-title":"Regulatory T-cell transcriptomic reprogramming characterizes adverse events by checkpoint inhibitors in solid tumors","volume":"9","author":"Grigoriou","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.991433","article-title":"Checkpoint inhibitor immune-related adverse events: A focused review on autoantibodies and B cells as biomarkers, advancements and future possibilities","volume":"13","author":"Taylor","year":"2023","journal-title":"Front Immunol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1172\/JCI99036","article-title":"B cells as biomarkers: predicting immune checkpoint therapy adverse events","volume":"128","author":"Liudahl","year":"2018","journal-title":"J Clin Invest"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac161","article-title":"Endocrine autoantibodies determine immune checkpoint inhibitor-induced endocrinopathy: A prospective study","volume":"107","author":"Labadzhyan","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1172\/JCI96798","article-title":"Early B cell changes predict autoimmunity following combination immune checkpoint blockade","volume":"128","author":"Das","year":"2018","journal-title":"J Clin Invest"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aai8153","article-title":"Low CD21 expression defines a population of recent germinal center graduates primed for plasma cell differentiation","volume":"2","author":"Lau","year":"2017","journal-title":"Sci Immunol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01637","article-title":"T follicular helper cells in autoimmune disorders","volume":"9","author":"Gensous","year":"2018","journal-title":"Front Immunol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41467-022-28120-2","article-title":"Lymphocyte infiltration and thyrocyte destruction are driven by stromal and immune cell components in hashimoto\u2019s thyroiditis","volume":"13","author":"Zhang","year":"2022","journal-title":"Nat Commun"},{"key":"B84","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40164-020-00167-1","article-title":"The effects of B cell depletion on immune related adverse events associated with immune checkpoint inhibition","volume":"9","author":"Risbjerg","year":"2020","journal-title":"Exp Hematol Oncol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac059","article-title":"Association of antithyroid antibodies in checkpoint inhibitor\u2013associated thyroid immune\u2013related adverse events","volume":"107","author":"Muir","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004008","article-title":"Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition","volume":"10","author":"Ghosh","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.5603\/EP.2014.0021","article-title":"The role of the immune system and cytokines involved in the pathogenesis of autoimmune thyroid disease (AITD)","volume":"65","author":"Miko\u015b","year":"2014","journal-title":"Endokrynologia Polska"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2006.08.015","article-title":"Modulation of autoimmunity by the latest interleukins (with special emphasis on IL-32)","volume":"6","author":"Conti","year":"2007","journal-title":"Autoimmun Rev"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14363","article-title":"Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors","volume":"111","author":"Kurimoto","year":"2020","journal-title":"Cancer Sci"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1458488","article-title":"Biomarkers in the early stage of PD-1 inhibitor treatment have shown superior predictive capabilities for immune-related thyroid dysfunction","volume":"15","author":"Liu","year":"2024","journal-title":"Front Immunol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2010.4","article-title":"IL-1 pathways in inflammation and human diseases","volume":"6","author":"Gabay","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nrrheum.2015.161","article-title":"Targeting GM-CSF in inflammatory diseases","volume":"12","author":"Wicks","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0046-y","article-title":"Biology and regulation of IL-2: from molecular mechanisms to human therapy","volume":"18","author":"Spolski","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102763","article-title":"Interleukin 1\u03b1: a comprehensive review on the role of IL-1\u03b1 in the pathogenesis and treatment of autoimmune and inflammatory diseases","volume":"20","author":"Cavalli","year":"2021","journal-title":"Autoimmun Rev"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1136\/gut.48.3.326","article-title":"Increased expression of IL-16 in inflammatory bowel disease","volume":"48","author":"Seegert","year":"2001","journal-title":"Gut"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2014.134","article-title":"New insights into IL-12-mediated tumor suppression","volume":"22","author":"Tugues","year":"2015","journal-title":"Cell Death Differ"},{"key":"B97","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41577-022-00746-9","article-title":"IL-17 and IL-17-producing cells in protection versus pathology","volume":"23","author":"Mills","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3858\/emm.2008.40.2.237","article-title":"IL-17 induces the production of IL-16 in rheumatoid arthritis","volume":"40","author":"Cho","year":"2008","journal-title":"Exp Mol Med"},{"key":"B99","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1038\/s41467-025-57603-1","article-title":"Interleukin-16 enhances anti-tumor immune responses by establishing a Th1 cell-macrophage crosstalk through reprogramming glutamine metabolism in mice","volume":"16","author":"Wen","year":"2025","journal-title":"Nat Commun"},{"key":"B100","doi-asserted-by":"publisher","first-page":"110989","DOI":"10.1016\/j.celrep.2022.110989","article-title":"Early IFN\u03b2 secretion determines variable downstream IL-12p70 responses upon TLR4 activation","volume":"39","author":"Posseme","year":"2022","journal-title":"Cell Rep"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107598","article-title":"MCP-1: Function, regulation, and involvement in disease","volume":"101","author":"Singh","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.27180","article-title":"The pathogenesis of thyroid autoimmune diseases: New T lymphocytes \u2013 Cytokines circuits beyond the Th1\u2013Th2 paradigm","volume":"234","author":"Li","year":"2019","journal-title":"J Cell Physiol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.it.2021.02.006","article-title":"Predicting and preventing immune checkpoint inhibitor toxicity: targeting cytokines","volume":"42","author":"Kang","year":"2021","journal-title":"Trends Immunol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2018.11.009","article-title":"Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors","volume":"107","author":"Hasan Ali","year":"2019","journal-title":"Eur J Cancer"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.46400","article-title":"Analysis of human leukocyte antigen DR alleles, immune-related adverse events, and survival associated with immune checkpoint inhibitor use among patients with advanced Malignant melanoma","volume":"5","author":"Akturk","year":"2022","journal-title":"JAMA Netw Open"},{"key":"B106","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ejca.2022.05.021","article-title":"Human leucocyte antigen genotype association with the development of immune-related adverse events in patients with non-small cell lung cancer treated with single agent immunotherapy","volume":"172","author":"Abed","year":"2022","journal-title":"Eur J Cancer"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.143","article-title":"HLA variation and disease","volume":"18","author":"Dendrou","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1080\/1750743X.2024.2353539","article-title":"Association between specific human leukocyte antigen alleles and development of thyroid immune-related adverse event","volume":"16","author":"Sasaki","year":"2024","journal-title":"Immunotherapy"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2016.00120","article-title":"Thyrotropin receptor epitope and human leukocyte antigen in graves\u2019 Disease","volume":"7","author":"Inaba","year":"2016","journal-title":"Front Endocrinol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0216941","article-title":"HLA alleles, especially amino-acid signatures of HLA-DPB1, might contribute to the molecular pathogenesis of early-onset autoimmune thyroid disease","volume":"14","author":"Shin","year":"2019","journal-title":"PloS One"},{"key":"B111","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1186\/s12885-025-13857-y","article-title":"Association of HLA-A*02:01 type with efficacy and toxicity of immune checkpoint inhibitor therapy in melanoma patients: a retrospective cohort study","volume":"25","author":"Manger","year":"2025","journal-title":"BMC Cancer"},{"key":"B112","doi-asserted-by":"publisher","first-page":"e34442","DOI":"10.1371\/journal.pone.0034442","article-title":"Novel associations for hypothyroidism include known autoimmune risk loci","volume":"7","author":"Eriksson","year":"2012","journal-title":"PloS One"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01614-3","article-title":"Hypothyroidism","volume":"404","author":"Taylor","year":"2024","journal-title":"Lancet"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-023-09848-8","article-title":"The genetics of Graves\u2019 disease","volume":"25","author":"Grixti","year":"2024","journal-title":"Rev Endocr Metab Disord"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113269","article-title":"Association between programmed death protein 1-related single-nucleotide polymorphisms and immune-related adverse events induced by programmed death protein 1 inhibitors\u2014a pilot study","volume":"143","author":"Cai","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02094-6","article-title":"Germline variants associated with toxicity to immune checkpoint blockade","volume":"28","author":"Groha","year":"2022","journal-title":"Nat Med"},{"key":"B117","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.1038\/s41467-021-23661-4","article-title":"Genetic variation associated with thyroid autoimmunity shapes the systemic immune response to PD-1 checkpoint blockade","volume":"12","author":"Khan","year":"2021","journal-title":"Nat Commun"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1584675\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:15:01Z","timestamp":1748996101000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1584675\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":117,"alternative-id":["10.3389\/fendo.2025.1584675"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1584675","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,4]]},"article-number":"1584675"}}